What is Zacks Research’s Forecast for Humana Q2 Earnings?

Humana Inc. (NYSE:HUM) – Equities researchers at Zacks Research increased their Q2 2026 earnings per share (EPS) estimates for Humana in a report released on Thursday, May 14th. Zacks Research analyst Team now anticipates that the insurance provider will earn $4.71 per share for the quarter, up from their previous estimate of $4.70. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Humana’s current full-year earnings is $9.06 per share. Zacks Research also issued estimates for Humana’s Q3 2026 earnings at $0.08 EPS, Q4 2026 earnings at ($6.08) EPS, FY2026 earnings at $9.01 EPS, Q2 2027 earnings at $4.19 EPS, Q3 2027 earnings at $2.31 EPS, Q4 2027 earnings at ($1.92) EPS, Q1 2028 earnings at $8.57 EPS and FY2028 earnings at $22.23 EPS.

Other equities research analysts also recently issued research reports about the stock. Wolfe Research decreased their target price on shares of Humana from $325.00 to $250.00 and set an “outperform” rating for the company in a research note on Monday, April 6th. Piper Sandler reaffirmed a “neutral” rating and set a $254.00 price objective (up from $182.00) on shares of Humana in a research note on Wednesday. Evercore increased their price objective on Humana from $195.00 to $250.00 in a research report on Thursday, April 30th. Morgan Stanley reiterated an “underweight” rating on shares of Humana in a research note on Friday. Finally, Truist Financial upped their price target on Humana from $220.00 to $270.00 and gave the stock a “hold” rating in a research note on Thursday, April 30th. Seven analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $246.83.

Humana Trading Down 1.4%

NYSE HUM opened at $300.52 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.77 and a current ratio of 1.77. The firm has a market cap of $36.08 billion, a PE ratio of 32.14, a P/E/G ratio of 2.82 and a beta of 0.68. Humana has a one year low of $163.11 and a one year high of $315.35. The firm’s fifty day moving average is $202.73 and its two-hundred day moving average is $226.49.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, April 29th. The insurance provider reported $10.31 EPS for the quarter, beating the consensus estimate of $9.97 by $0.34. The firm had revenue of $39.65 billion during the quarter, compared to the consensus estimate of $39.37 billion. Humana had a net margin of 0.82% and a return on equity of 10.45%. Humana’s revenue for the quarter was up 23.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $11.58 EPS. Humana has set its FY 2026 guidance at 9.000- EPS.

Humana Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Friday, June 26th will be given a dividend of $0.885 per share. The ex-dividend date is Friday, June 26th. This represents a $3.54 annualized dividend and a yield of 1.2%. Humana’s payout ratio is presently 37.86%.

Insider Activity

In other Humana news, insider Sanjay K. Shetty purchased 810 shares of Humana stock in a transaction dated Monday, February 23rd. The stock was acquired at an average cost of $185.21 per share, with a total value of $150,020.10. Following the acquisition, the insider directly owned 11,657 shares of the company’s stock, valued at $2,158,992.97. This represents a 7.47% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.20% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in Humana by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 14,261,860 shares of the insurance provider’s stock valued at $3,652,890,000 after acquiring an additional 106,030 shares during the period. Capital International Investors grew its stake in shares of Humana by 113.9% during the 4th quarter. Capital International Investors now owns 5,818,008 shares of the insurance provider’s stock worth $1,490,239,000 after purchasing an additional 3,097,571 shares during the period. Pzena Investment Management LLC increased its holdings in shares of Humana by 34.3% in the 1st quarter. Pzena Investment Management LLC now owns 5,470,982 shares of the insurance provider’s stock valued at $948,614,000 after purchasing an additional 1,398,774 shares in the last quarter. State Street Corp increased its holdings in shares of Humana by 1.8% in the 4th quarter. State Street Corp now owns 5,462,549 shares of the insurance provider’s stock valued at $1,403,877,000 after purchasing an additional 97,211 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its stake in shares of Humana by 28.9% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,496,775 shares of the insurance provider’s stock valued at $1,151,759,000 after purchasing an additional 1,008,514 shares during the period. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Key Headlines Impacting Humana

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Piper Sandler raised its price target on Humana to $254 from $182 while keeping a Neutral rating, suggesting improved confidence in the company’s outlook. Piper Sandler price target increase article
• Positive Sentiment: Humana, CenterWell and USAA announced a veterans-focused community service initiative with the VFW, which may support the company’s brand and social impact reputation. Veterans Day of Service article
• Neutral Sentiment: Humana also announced more than $1 million in Louisiana health-outcome grants, a positive corporate initiative that is unlikely to move the stock much on its own. Louisiana grants article
• Negative Sentiment: Zacks Research cut Humana’s FY2026 EPS estimate to $9.01 from $9.90, signaling softer near-term earnings expectations.
• Negative Sentiment: The firm also lowered estimates for FY2027, Q2 2027, Q4 2027 and Q1 2028, reinforcing concerns that earnings momentum may be uneven.
• Negative Sentiment: Zacks Research maintains a Strong Sell rating on Humana, which adds to pressure on the shares.

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.